Clinical TrialJul 15, 2026, 04:19 PM
Azitra Announces Breakthrough Anti-Wrinkle Ex Vivo Results for ATR-COSF
AI Summary
Azitra, Inc. announced promising results from two separate ex vivo human skin tissue studies for its ATR-COSF program, which develops a high-value cosmetic ingredient based on a recombinant human filaggrin protein. The first study demonstrated increased penetration and distribution of the filaggrin into the stratum granulosum with repeat dosing. The second study showed a dose-dependent increase in skin elasticity, with up to a 4.4-fold enhancement, indicating potential for anti-wrinkle applications. The company plans to optimize formulations and proceed to human studies.
Key Highlights
- ATR-COSF program uses a supernatant containing recombinant human filaggrin (rHDfilaggrin).
- Repeat dose ex vivo data showed increased rHDfilaggrin distribution into the stratum granulosum.
- Single dose ex vivo experiments established improvements in elasticity and reduced appearance of fine lines/wrinkles.
- A 7.5% w/w concentration of the supernatant increased skin elasticity by 4.4-fold.
- A 0.09% w/w concentration of the supernatant increased skin elasticity by 1.6-fold.
- A 0.28% w/w concentration restored ex vivo skin elasticity to values observed in healthy skin.
- Safety testing demonstrated the 2% supernatant formulation is non-irritating and non-corrosive.
Price Impact
More from AZTR